Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Risk “Concept Papers” Expected In March; April Workshop Set

Executive Summary

FDA hopes to release three "concept papers" on risk assessment and risk management March 10 as the first step in developing risk guidances mandated under the Prescription Drug User Fee Act reauthorization
Advertisement

Related Content

PhRMA Wants Clearer Definition Of Safety “Signal”; FDA Proposes Newsletter
PhRMA Wants Clearer Definition Of Safety “Signal”; FDA Proposes Newsletter
Pharmacoepidemiologic Studies Should Estimate AE Background Rates – FDA
Rx Name Risk Assessments Should Be Conducted By Manufacturers, FDA Says
NDA Reviews To Be Studied Prospectively To Identify Best First-Cycle Practices
PDUFA 2.5?: Delay In FY 2003 FDA Appropriations Has PDUFA III In Limbo
FDA Rx Risk Assessment Guidance May Detail Lab Test Parameters
FDA Emphasizing Written Communication With Sponsors On Pending NDAs
PDUFA III Implementation Begins: FDA Working Groups Under Way
PDUFA III Implementation Begins: FDA Working Groups Under Way
Advertisement
UsernamePublicRestriction

Register

PS041125

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel